A private placement to raise up to $2,000,000 (100,000,000 securities) at an issue price of A$0.02 (2 cents) (NZ$0.022), with the ability to take oversubscriptions at the company’s discretion.

Subject to shareholder approval, investors will receive one (1) free attaching unlisted option for every one (1) placement share subscribed for under the offer. The attaching options will have an exercise price of A$0.02 (2 cents) (NZ$0.022) and an expiry date of 30 June 2026.

TruScreen Group Limited (ASX/NZX: TRU) is a dual-listed medtech company focused on the global rollout of its AI-enabled cervical cancer screening device, TruScreen Ultra®.

The handheld device offers real-time results without requiring laboratory infrastructure, sample collection, or specialist personnel, making it particularly suited for low and middle-income countries

TruScreen’s solution has been clinically validated and is approved for use in more than 25 countries, including China, Australia, Vietnam, and Saudi Arabia

The TruScreen Ultra® device uses low-level electrical and optical signals to analyse cervical tissue through a disposable Single Use Sensor

Its AI algorithm compares data to a global database to detect abnormalities in minutes

The system has demonstrated strong clinical performance, including 87.5% sensitivity and 88.4% specificity, and has been used to screen over 1 million women with no adverse events reported.

Key benefits include:

• No samples or lab processing required
• Real-time results and rapid diagnosis
• Portable and easy to use in remote settings
• Safe, painless, and highly scalable
• Recurring revenue via consumables (SUS) 

China – Core revenue market with 477 million women of screening age, supported by guideline inclusion and dual NMPA device approval

India – Distributor-led re-entry in a 468-million-woman market

Vietnam – National program targeting 60% screening coverage

Unlike traditional methods such as Pap smears or HPV testing, TruScreen's AI-enabled system serves as a standalone primary screening tool.

• This makes it particularly suitable for deployment in regions lacking extensive medical infrastructure
• The device holds CE Mark certification for Europe and approval from China's National Medical Products Administration, facilitating its use in multiple international markets

Commercial focus on countries with high cervical cancer mortality and low screening rates

• TRU's capital-light solution provides a clear advantage over traditional methods
• TRU has active operations across Asia, Africa, and Latin America, and now has a presence in three of the world’s four most populous countries: China, India, and Indonesia